Pediatric low-grade gliomas (pLGG) show heterogeneous responses to MAPK inhibitors
(MAPKi) in clinical trials. Thus, more complex stratification biomarkers are needed to identify …

Purpose: PNOC003 is a multicenter precision medicine trial for children and young adults
with newly diagnosed diffuse intrinsic pontine glioma (DIPG). Patients and Methods: Patients …

Pediatric brain tumors are the leading cause of cancer-related death in children in the
United States and contribute a disproportionate number of potential years of life lost …

With the success of immunotherapy in cancer, understanding the tumor immune
microenvironment (TIME) has become increasingly important; however in pediatric brain …

Glioblastoma multiforme (GBM) is one of the most common and aggressive type of
malignant glioma with an average survival time of 12–18 mo. Despite the utilization of …

Background Pediatric brain tumors are the leading cause of cancer death in children with an
urgent need for innovative therapies. Glypican 2 (GPC2) is a cell surface oncoprotein …

Objectives Despite surgical resection, chemoradiation, and targeted therapy, brain tumors
remain a leading cause of cancer-related death in children. Immunotherapy has shown …

Structural variation heavily influences the molecular landscape of cancer, in part by
impacting DNA methylation-mediated transcriptional regulation. Here, using multi-omic …

In order to better understand the relationship between normal and neoplastic brain, we
combined five publicly available large-scale datasets, correcting for batch effects and …

Pediatric low-grade gliomas (pLGGs) exhibit heterogeneous prognoses and variable
responses to treatment, leading to tumor progression and adverse outcomes in cases where …